USP9X can bind and remove polyubiquitin chains from MCL1 targeted for degradation, and its expression correlates with MCL1 overexpression in follicular lymphoma, diffuse large B-cell lymphoma, and multiple myeloma. The gene discussed is MCL1; the disease is follicular lymphoma.